PriceTargets.com logo

NASDAQ:ATRA - Atara Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.33
  • Forecasted Upside: 89.23 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$16.03 As of 10/22/2021 05:00 PM ET
▲ +0.22 (1.39%)

This chart shows the closing price for ATRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atara Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRA

Analyst Price Target is $30.33
▲ +89.23% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $30.33, with a high forecast of $41.00 and a low forecast of $27.00. The average price target represents a 89.23% upside from the last price of $16.03.

This chart shows the closing price for ATRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Atara Biotherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021MizuhoInitiated CoverageBuy$41.00High
10/5/2021HC WainwrightReiterated RatingBuy$31.00Low
10/4/2021Stifel NicolausLower Price TargetBuy$30.00 ➝ $27.00Low
9/29/2021MizuhoInitiated CoverageBuy$41.00High
9/28/2021HC WainwrightReiterated RatingBuy$31.00High
5/13/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$23.00 ➝ $29.00Low
5/5/2021HC WainwrightLower Price TargetBuy$32.00 ➝ $31.00High
3/2/2021William BlairReiterated RatingOutperformLow
3/2/2021CitigroupUpgradeNeutral ➝ Buy$27.00High
12/9/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$20.00 ➝ $27.00High
12/8/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $31.00Medium
12/7/2020Stifel NicolausBoost Price TargetBuy$28.00 ➝ $33.00Medium
11/23/2020MizuhoBoost Price TargetBuy$38.00 ➝ $41.00Low
11/13/2020Smith Barney CitigroupBoost Price Target$14.00 ➝ $20.00Low
11/10/2020HC WainwrightBoost Price TargetBuy$26.00 ➝ $28.00High
9/24/2020William BlairReiterated RatingBuyHigh
9/14/2020Canaccord GenuityBoost Price TargetBuy$70.00 ➝ $78.00Medium
8/6/2020Stifel NicolausLower Price TargetBuy$30.00 ➝ $28.00Low
8/6/2020HC WainwrightBoost Price TargetBuy$25.00 ➝ $26.00High
7/17/2020Canaccord GenuityReiterated RatingBuy$70.00Medium
6/30/2020Evercore ISIInitiated CoverageOutperformMedium
6/15/2020HC WainwrightInitiated CoverageBuy$25.00High
5/26/2020MizuhoInitiated CoverageBuy$38.00High
5/19/2020MizuhoInitiated CoverageBuy$38.00High
5/12/2020JPMorgan Chase & Co.Boost Price TargetNeutral$22.00 ➝ $23.00High
4/23/2020CitigroupUpgradeNeutral ➝ Buy$14.00High
2/18/2020Canaccord GenuityReiterated RatingBuyHigh
12/10/2019CowenReiterated RatingBuyMedium
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$43.00 ➝ $22.00Low
10/25/2019Stifel NicolausReiterated RatingBuyLow
9/27/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$14.00 ➝ $9.00Medium
9/18/2019MizuhoSet Price TargetBuy$43.00Low
9/16/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $15.00Medium
9/13/2019Stifel NicolausSet Price TargetBuy$36.00Low
9/13/2019CowenReiterated RatingBuyHigh
9/13/2019Roth CapitalInitiated CoverageBuy$30.00High
9/11/2019MizuhoSet Price TargetBuy$43.00Medium
8/12/2019CitigroupSet Price TargetHold$14.00High
7/16/2019CowenReiterated RatingBuyHigh
7/1/2019Canaccord GenuityReiterated RatingBuy$70.00Medium
6/3/2019CitigroupUpgradeSell ➝ Neutral$23.00 ➝ $24.00High
5/30/2019Roth CapitalInitiated CoverageBuy$30.00Medium
5/29/2019WedbushReiterated RatingOutperformHigh
5/22/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$41.00Low
5/16/2019William BlairReiterated RatingBuyLow
5/9/2019MizuhoReiterated RatingBuy$62.00High
4/21/2019MizuhoReiterated RatingBuy$62.00Low
4/1/2019William BlairReiterated RatingOutperformLow
2/26/2019CowenReiterated RatingBuyHigh
2/26/2019MizuhoReiterated RatingBuy$62.00High
1/22/2019MizuhoInitiated CoverageBuy ➝ Buy$62.00Low
11/30/2018CowenReiterated RatingBuyHigh
8/3/2018Jefferies Financial GroupReiterated RatingBuy$45.00Low
6/11/2018CitigroupLower Price TargetSell ➝ Sell$25.00 ➝ $23.00Medium
5/8/2018Canaccord GenuityReiterated RatingBuy$70.00Medium
4/10/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$56.00High
4/6/2018William BlairReiterated RatingBuyMedium
3/20/2018William BlairReiterated RatingOutperformHigh
3/15/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
3/13/2018Canaccord GenuityReiterated RatingBuy$70.00Low
3/5/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$30.00 ➝ $46.00High
2/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
2/15/2018CitigroupDowngradeNeutral ➝ SellHigh
1/26/2018CowenInitiated CoverageOutperformHigh
1/19/2018Canaccord GenuityReiterated RatingBuy ➝ Positive$47.00 ➝ $70.00Low
1/3/2018CitigroupUpgradeSell ➝ Neutral$18.00High
12/29/2017Canaccord GenuityReiterated RatingBuyLow
11/9/2017Canaccord GenuityReiterated RatingBuyN/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$20.00N/A
10/5/2017Jefferies Financial GroupReiterated RatingBuy$30.00N/A
9/11/2017Canaccord GenuityReiterated RatingBuy$47.00High
8/31/2017Jefferies Financial GroupReiterated RatingBuy$30.00High
8/7/2017Canaccord GenuitySet Price TargetBuy$47.00High
6/26/2017William BlairReiterated RatingOutperformMedium
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$30.00Medium
4/21/2017Canaccord GenuityReiterated RatingBuy$47.00Medium
3/16/2017CitigroupSet Price TargetSell$10.00High
3/11/2017Canaccord GenuitySet Price TargetBuy$47.00High
1/18/2017Canaccord GenuitySet Price TargetBuy$47.00N/A
12/12/2016Canaccord GenuitySet Price TargetBuy$47.00N/A
12/12/2016Jefferies Financial GroupSet Price TargetBuy$23.00N/A
12/6/2016Canaccord GenuitySet Price TargetBuy$47.00N/A
11/6/2016Canaccord GenuitySet Price TargetBuy$47.00N/A
10/24/2016Jefferies Financial GroupInitiated CoverageBuy$25.00 ➝ $23.00N/A
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2021
  • 3 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/24/2021

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Atara Biotherapeutics logo
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $16.03
Low: $15.55
High: $16.06

50 Day Range

MA: $15.40
Low: $11.99
High: $17.98

52 Week Range

Now: $16.03
Low: $11.81
High: $28.20

Volume

593,692 shs

Average Volume

849,668 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Atara Biotherapeutics?

The following equities research analysts have issued reports on Atara Biotherapeutics in the last twelve months: Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Mizuho, Smith Barney Citigroup, Stifel Nicolaus, William Blair, and Zacks Investment Research.
View the latest analyst ratings for ATRA.

What is the current price target for Atara Biotherapeutics?

6 Wall Street analysts have set twelve-month price targets for Atara Biotherapeutics in the last year. Their average twelve-month price target is $30.33, suggesting a possible upside of 89.2%. Mizuho has the highest price target set, predicting ATRA will reach $41.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $27.00 for Atara Biotherapeutics in the next year.
View the latest price targets for ATRA.

What is the current consensus analyst rating for Atara Biotherapeutics?

Atara Biotherapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATRA will outperform the market and that investors should add to their positions of Atara Biotherapeutics.
View the latest ratings for ATRA.

How do I contact Atara Biotherapeutics' investor relations team?

Atara Biotherapeutics' physical mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 278-8930 and its investor relations email address is [email protected] The official website for Atara Biotherapeutics is www.atarabio.com.